搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Burkholderia mallei Putative Holliday junction resolvase (BMASAVP1_A0917) CSB-YP379209BPR
CSB-EP379209BPR
CSB-BP379209BPR
CSB-MP379209BPR
CSB-EP379209BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei Chaperone protein htpG (htpG), partial CSB-YP379210BPR
CSB-EP379210BPR
CSB-BP379210BPR
CSB-MP379210BPR
CSB-EP379210BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei Coproporphyrinogen-III oxidase, aerobic (hemF) CSB-YP379211BPR
CSB-EP379211BPR
CSB-BP379211BPR
CSB-MP379211BPR
CSB-EP379211BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei Methylglyoxal synthase (mgsA) CSB-YP379212BPR
CSB-EP379212BPR
CSB-BP379212BPR
CSB-MP379212BPR
CSB-EP379212BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei 30S ribosomal protein S15 (rpsO) CSB-YP379213BPR
CSB-EP379213BPR
CSB-BP379213BPR
CSB-MP379213BPR
CSB-EP379213BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei NADH-quinone oxidoreductase subunit B 1 (nuoB1) CSB-YP379214BPR
CSB-EP379214BPR
CSB-BP379214BPR
CSB-MP379214BPR
CSB-EP379214BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei NADH-quinone oxidoreductase subunit I (nuoI) CSB-YP379215BPR
CSB-EP379215BPR
CSB-BP379215BPR
CSB-MP379215BPR
CSB-EP379215BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei Phosphomethylpyrimidine synthase (thiC), partial CSB-YP379216BPR
CSB-EP379216BPR
CSB-BP379216BPR
CSB-MP379216BPR
CSB-EP379216BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei Alanine--tRNA ligase (alaS), partial CSB-YP379217BPR
CSB-EP379217BPR
CSB-BP379217BPR
CSB-MP379217BPR
CSB-EP379217BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei Chorismate synthase (aroC) CSB-YP379218BPR
CSB-EP379218BPR
CSB-BP379218BPR
CSB-MP379218BPR
CSB-EP379218BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei 50S ribosomal protein L35 (rpmI) CSB-YP379219BPR
CSB-EP379219BPR
CSB-BP379219BPR
CSB-MP379219BPR
CSB-EP379219BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei Ribose-5-phosphate isomerase A (rpiA) CSB-YP379220BPR
CSB-EP379220BPR
CSB-BP379220BPR
CSB-MP379220BPR
CSB-EP379220BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei Probable potassium transport system protein kup (kup), partial CSB-YP379221BPR
CSB-EP379221BPR
CSB-BP379221BPR
CSB-MP379221BPR
CSB-EP379221BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei Recombination protein RecR (recR) CSB-YP379222BPR
CSB-EP379222BPR
CSB-BP379222BPR
CSB-MP379222BPR
CSB-EP379222BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei 30S ribosomal protein S6 (rpsF) CSB-YP379223BPR
CSB-EP379223BPR
CSB-BP379223BPR
CSB-MP379223BPR
CSB-EP379223BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei Probable intracellular septation protein A (BMASAVP1_A1933), partial CSB-YP379224BPR1
CSB-EP379224BPR1
CSB-BP379224BPR1
CSB-MP379224BPR1
CSB-EP379224BPR1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (ispF) CSB-YP379225BPR
CSB-EP379225BPR
CSB-BP379225BPR
CSB-MP379225BPR
CSB-EP379225BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei Putative phosphotransferase BMASAVP1_A2039 (BMASAVP1_A2039) CSB-YP379226BPR
CSB-EP379226BPR
CSB-BP379226BPR
CSB-MP379226BPR
CSB-EP379226BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei UDP-3-O-acylglucosamine N-acyltransferase (lpxD) CSB-YP379227BPR
CSB-EP379227BPR
CSB-BP379227BPR
CSB-MP379227BPR
CSB-EP379227BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia mallei [Protein-PII] uridylyltransferase (glnD), partial CSB-YP379228BPR
CSB-EP379228BPR
CSB-BP379228BPR
CSB-MP379228BPR
CSB-EP379228BPR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問(wèn)題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>